左捆支部阻塞诱导的扩张性心肌病:定义,病理生理学和治疗方法
Catarina Amaral Marques1, Ana Laura Costa2, Elisabete Martins1
1Faculty of Medicine - University of Porto, Porto, Portugal; Department of Cardiology, Centro Hospitalar Universitário São João, Porto, Portugal.
概括
左捆支部阻塞 (LBBB) 可能导致扩张性心肌病 (DCM). 早期心脏再同步治疗 (CRT) 可能会改善LBBB诱导的DCM (LBBB-iDCM) 患者的左心室功能,但缺乏诊断标准.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭研究研究
背景情况:
- 左捆支部阻塞 (LBBB) 在心力衰竭 (HF) 中很常见,特别是在扩张性心肌病 (DCM) 中.
- 从历史上看,LBBB一直被视为DCM的后果.
- 最近的观察表明,LBBB可能会诱导DCM (LBBB-iDCM),一个不同的实体.
研究的目的:
- 审查LBBB诱导扩张性心肌病变 (LBBB-iDCM) 的病理生理学.
- 讨论LBBB-iDCM目前的诊断标准.
- 概述为LBBB-iDCM提出的治疗策略.
主要方法:
- 关于LBBB-iDCM病理生理学的文献综述.
- 对拟议的诊断标准进行分析.
- 综合当前的治疗方法.
主要成果:
- 证据支持LBBB-iDCM作为一种特定的病理实体.
- 患有LBBB-iDCM的患者可能会从早期的心脏再同步治疗 (CRT) 中受益.
- 目前没有LBBB-iDCM的最终诊断标准和治疗指南.
结论:
- 认可LBBB-iDCM对HF管理具有重大临床影响.
- 早期CRT可能是LBBB-iDCM的一个有利的策略.
- 需要进一步的研究来建立通用诊断标准和治疗方案.
相关概念视频
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Pathophysiology of Cardiac Performance
645
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
645
Heart Failure Drugs: Inotropic Agents
577
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577


